Functional near-infrared fluorescence imaging for cardiac surgery and targeted gene therapy

Molecular Imaging

Volumn 1, Issue 4, 2002, Pages 365-377

  Nakayama, Akira ^a   Del Monte, Federica ^b   Hajjar, Roger J ^b   Frangioni, John V ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Angiography; Cardiac surgery; Gene therapy; Imaging; Near infrared fluorescence

Indexed keywords

BIOLOGICAL ORGANS; CARDIOLOGY; CARDIOVASCULAR SURGERY; FLUORESCENCE; GENES; HEMODYNAMICS; IMAGING SYSTEMS; INFRARED SPECTROSCOPY; MODELS;

CARDIAC REVASCULARIZATION; CARDIAC SURGERY; GENE THERAPY; NEAR-INFRARED FLUORESCENCE IMAGING; REALTIME VISUAL ASSESSMENT; SURGICAL IMAGING SYSTEM;

MEDICAL IMAGING;

DIAGNOSTIC AGENT; FLUORESCENT DYE;

ANIMAL; ARTICLE; GENE THERAPY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART SURGERY; HUMAN; INSTRUMENTATION; INTRAOPERATIVE PERIOD; METHODOLOGY; NEAR INFRARED SPECTROSCOPY; NECROSIS; PATHOLOGY; RAT;

ANIMALS; CARDIAC SURGICAL PROCEDURES; FLUORESCENT DYES; GENE THERAPY; HUMANS; INTRAOPERATIVE PERIOD; MYOCARDIAL ISCHEMIA; MYOCARDIAL REVASCULARIZATION; NECROSIS; RATS; SPECTROSCOPY, NEAR-INFRARED;

EID: 0043132443     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.1162/153535002321093972     Document Type: Article

References (33)

1. 2002 Heart and stroke statistical update. 2001, Dallas, TX: American Heart Association.
2. Kolesov VI (1978). Basic trends in the development of coronary surgery. Vestn Khir Im I I Grek. 121: 3-7.
3. Carey JS, Cukingnan RA (1978). Veterans Administration cooperative study of surgery for coronary arterial occlusive disease-I. Am J Cardio.l 42:333-334.
4. McCall D, Katz AM (1978). Veterans Administration cooperative study of surgery for coronary arterial occlusive disease-II. Am J Cardiol. 42:334-335.
5. Coronary-artery bypass surgery in stable angina pectoris: Survival at two years. European Coronary Surgery Study Group. Lancet, 1979. 1:889-893.
6. Laham RJ, Chronos NA, Pike M, Leimbach ME, Udelson JE, Pearlman JD, Pettigrew RI, Whitehouse MJ, Yoshizawa C, Simons M (2000). Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a phase I open-label dose escalation study. J Am Coll Cardiol. 36:2132-2139.
7. Lathi KG, Vale PR, Losordo DW, Cespedes RM, Symes JF, Esakof DD, Maysky M, Isner JM (2001). Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: Anesthetic management and results. Anesth Analg. 92: 19-25.
8. Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch R, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, Crystal RG (1999). Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation. 100:468-474.
9. Dumont EA, Reutelingsperger CP, Smits JF, Daemen MJ, Doevendans PA, Wellens HJ, Hofstra L (2001). Real-time imaging of apoptotic cell-membrane changes at the single-cell level in the beating murine heart. Nat Med. 7:1352-1355.
10. Chance B (1998). Near-infrared images using continuous, phase-modulated, and pulsed light with quantitation of blood and blood oxygenation. Ann NY Acad Sci. 838:29-45.
11. Zaheer A, Lenkinski RE, Mahmood A, Jones AG, Cantley LC, Frangioni JV (2001). In vivo near-infrared fluorescence imaging of osteoblastic activity. Nat Biotechnol. 19:1148-1154.
12. Zaheer A, Wheat TE, Frangioni JV (2002). IRDye78 conjugates for near-infrared fluorescence imaging. Mol Imaging. 1:354-364.
13. 131I]Iodorhodamine: Synthesis, cellular localization, and biodistribution in athymic mice bearing human tumor xenografts and comparison with [99mTc]hexakis(2-methoxyisobutylisonitrile). J Med Chem. 41:2111-2117.
14. Sima PD, Kanofsky JR (2000). Cyanine dyes as protectors of K562 cells from photosensitized cell damage. Photochem Photobiol. 71:413-421.
15. Imaizumi K, Nakamura K (2001). Fluorescent endoscope system enabling simultaneous normal light observation and fluorescence observation in infrared spectrum. In U.S.P.T.O. USA: Olympus Optical.
16. Sevick-Muraca EM, Lopez G, Reynolds JS, Troy TL, Hutchinson CL (1997). Fluorescence and absorption contrast mechanisms for biomedical optical imaging using frequency-domain techniques. Photochem Photobiol. 66:55-64.
17. Eppstein MJ, Hawrysz DJ, Godavarty A, Sevick-Muraca EM (2002). Three-dimensional, Bayesian image reconstruction from sparse and noisy data sets: Near-infrared fluorescence tomography. Proc Natl Acad Sci USA. 99:9619-9624.
18. Farkas DL, Du C, Fisher GW, Lau C, Niu W, Wachman ES, Levenson RM (1998). Non-invasive image acquisition and advanced processing in optical bioimaging. Comput Med Imaging Graph. 22:89-102.
19. Ntziachristos V, Yodh AG, Schnall M, Chance B (2000). Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. Proc Natl Acad Sci USA. 97: 2767-2772.
20. Chen J, Tung CH, Mahmood U, Ntziachristos V, Gyurko R, Fishman MC, Huang PL, Weissleder R (2002). In vivo imaging of proteolytic activity in atherosclerosis. Circulation. 105: 2766-2771.
21. Becker A, Hessenius C, Licha K, Ebert B, Sukowski U, Semmler W, Wiedenmann B, Grotzinger C (2001). Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat Biotechnol. 19:327-331.
22. Bugaj JE, Achilefu S, Dorshow RB, Rajagopalan R (2001). Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform. J Biomed Opt. 6: 122-133.
23. Mahmood U, Tung CH, Bogdanov A Jr., Weissleder R (1999). Near-infrared optical imaging of protease activity for tumor detection. Radiology. 213:866-870.
24. Weissleder R, Tung CH, Mahmood U, Bogdanov A (1999). In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol. 17:375-378.
25. Benson RC, Kues HA (1978). Fluorescence properties of indocyanine green as related to angiography. Phys Med Biol. 23:159-163.
26. Anderson WM, Delinck DL, Benninger L, Wood JM, Smiley ST, Chen LB (1993). Cytotoxic effect of thiacarbocyanine dyes on human colon carcinoma cells and inhibition of bovine heart mitochondrial NADH-ubiquinone reductase activity via a rotenone-type mechanism by two of the dyes. Biochem Pharmacol. 45:691-696.
27. Horvath KA (2000). Transmyocardial laser revascularization in the treatment of myocardial ischemia. J Card Surg. 15:271-277.
28. Nathan M, Aranki S (2001). Transmyocardial laser revascularization. Curr Opin Cardiol. 16:310-314.
29. Hajjar RJ, del MF, Matsui T, Rosenzweig A (2000). Prospects for gene therapy for heart failure. Circ Res. 86: 616-621.
30. Isner JM (2002). Myocardial gene therapy. Nature. 415:234-239.
31. Rosengart TK, Lee LY, Patel SR, Kligfield PD, Okin PM, Hackett NR, Isom OW, Crystal RG (1999). Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg. 230:466-470; discussion 470-472.
32. Simons M, Bonow RO, Chronos NA, Cohen DJ, Giordano FJ, Hammond HK, Laham RJ, Li W, Pike M, Sellke FW, Stegmann TJ, Udelson JE, Rosengart TK (2000). Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary. Circulation. 102:E73-E86.
33. Pouzet B, Vilquin JT, Hagege AA, Scorsin M, Messas E, Fiszman M, Schwartz K, Menasche P (2001). Factors affecting functional outcome after autologous skeletal myoblast transplantation. Ann Thorac Surg. 71:844-850; discussion 850-851.